{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:41:30Z","timestamp":1791805290770,"version":"4.3.4"},"reference-count":70,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA234212"],"award-info":[{"award-number":["P01 CA234212"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA169118"],"award-info":[{"award-number":["R01 CA169118"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA204419"],"award-info":[{"award-number":["R01 CA204419"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,10,17]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A first-in-human, randomized pilot phase II clinical trial combining vaccines targeting overexpressed, non-mutated tumor blood vessel antigens (TBVA) and tyrosine kinase inhibitor dasatinib was conducted in human leukocyte antigen (HLA)-A2<jats:sup>+<\/jats:sup> patients with advanced melanoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patient monocyte-derived type-1-polarized dendritic cells were loaded with HLA-A2-presented peptides derived from TBVA (DLK1, EphA2, HBB, NRP1, RGS5, TEM1) and injected intradermally as a vaccine into the upper extremities every other week. Patients were randomized into one of two treatment arms receiving oral dasatinib (70\u2009mg two times per day) beginning in week 5 (Arm A) or in week 1 (Arm B). Trial endpoints included T cell response to vaccine peptides (interferon-\u03b3 enzyme-linked immunosorbent spot), objective clinical response (Response Evaluation Criteria in Solid Tumors V.1.1) and exploratory tumor, blood and serum profiling of immune-associated genes\/proteins.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixteen patients with advanced-stage cutaneous (n=10), mucosal (n=1) or uveal (n=5) melanoma were accrued, 15 of whom had previously progressed on programmed cell death protein 1 (PD-1) blockade. Of 13 evaluable patients, 6 patients developed specific peripheral blood T cell responses against \u22653 vaccine-associated peptides, with further evidence of epitope spreading. All six patients with specific CD8<jats:sup>+<\/jats:sup> T cell response to vaccine-targeted antigens exhibited evidence of T cell receptor (TCR) convergence in association with preferred clinical outcomes (four partial response and two stabilization of disease (SD)). Seven patients failed to respond to vaccination (one SD and six progressive disease). Patients in Arm B (immediate dasatinib) outperformed those in Arm A (delayed dasatinib) for immune response rate (IRR; 66.7% vs 28.6%), objective response rate (ORR) (66.7% vs 0%), overall survival (median 15.45 vs 3.47 months; p=0.0086) and progression-free survival (median 7.87 vs 1.97 months; p=0.063). IRR (80% vs 25%) and ORR (60% vs 12.5%) was greater for females versus male patients. Tumors in patients exhibiting response to treatment displayed (1) evidence of innate and adaptive immune-mediated inflammation and TCR convergence at baseline, (2) on-treatment transcriptional changes associated with reduced hypoxia\/acidosis\/glycolysis, and (3) increased inflammatory immune cell infiltration and tertiary lymphoid structure neogenesis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Combined vaccination against TBVA plus dasatinib was safe and resulted in coordinating immunologic and\/or objective clinical responses in 6\/13 (46%) evaluable patients with melanoma, particularly those initiating treatment with both agents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01876212\">NCT01876212<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003675","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T11:13:24Z","timestamp":1636974804000},"page":"e003675","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":54,"title":["Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01876212","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04093323","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8961-4444","authenticated-orcid":false,"given":"Walter J","family":"Storkus","sequence":"first","affiliation":[{"name":"Dermatology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deena","family":"Maurer","sequence":"additional","affiliation":[{"name":"Translational and Regulatory Affairs, Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lin","sequence":"additional","affiliation":[{"name":"Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ding","sequence":"additional","affiliation":[{"name":"Biostatistics, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamika","family":"Bose","sequence":"additional","affiliation":[{"name":"Immunoregulation and Immunodiagnostics, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Lowe","sequence":"additional","affiliation":[{"name":"Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center, Abilene, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rose","sequence":"additional","affiliation":[{"name":"Clinical Research Services, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"DeMark","sequence":"additional","affiliation":[{"name":"Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilit","family":"Karapetyan","sequence":"additional","affiliation":[{"name":"Medicine, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Taylor","sequence":"additional","affiliation":[{"name":"Dermatology and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Chelvanambi","sequence":"additional","affiliation":[{"name":"Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J","family":"Fecek","sequence":"additional","affiliation":[{"name":"Microbiology and Immunology, LECOM, Greensburg, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica N","family":"Filderman","sequence":"additional","affiliation":[{"name":"Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J","family":"Looney","sequence":"additional","affiliation":[{"name":"Immunology, Singular Genomics, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Miller","sequence":"additional","affiliation":[{"name":"Molecular Biology, Thermo Fisher Scientific, Santa Clara, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Linch","sequence":"additional","affiliation":[{"name":"Molecular Biology, Thermo Fisher Scientific, Santa Clara, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-4165","authenticated-orcid":false,"given":"Geoffrey M","family":"Lowman","sequence":"additional","affiliation":[{"name":"Molecular Biology, Thermo Fisher Scientific, Santa Clara, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Kalinski","sequence":"additional","affiliation":[{"name":"Medical Oncology and Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3439-9844","authenticated-orcid":false,"given":"Lisa H","family":"Butterfield","sequence":"additional","affiliation":[{"name":"Research and Development, Parker Institute for Cancer Immunotherapy, San Francisco, California, USA"},{"name":"Microbiology and Immunology, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3193-9702","authenticated-orcid":false,"given":"Ahmad","family":"Tarhini","sequence":"additional","affiliation":[{"name":"Cutaneous Oncology and Immunology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-851X","authenticated-orcid":false,"given":"Hussein","family":"Tawbi","sequence":"additional","affiliation":[{"name":"Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"2025100308413841000_9.11.e003675.1","unstructured":"Cancer Facts and Figures 2020 . American Cancer Society, Atlanta, GA, USA, 2021. Available: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2021\/cancer-facts-and-figures-2021.pdf"},{"key":"2025100308413841000_9.11.e003675.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4799"},{"key":"2025100308413841000_9.11.e003675.3","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2016.07.10","article-title":"Toxicity management of immunotherapy for patients with metastatic melanoma","volume":"4","author":"Linardou","year":"2016","journal-title":"Ann Transl Med"},{"key":"2025100308413841000_9.11.e003675.4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00152","article-title":"Melanoma: from incurable beast to a curable BET. The success of immunotherapy","volume":"5","author":"Ascierto","year":"2015","journal-title":"Front Oncol"},{"key":"2025100308413841000_9.11.e003675.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.111"},{"key":"2025100308413841000_9.11.e003675.6","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e328346554d"},{"key":"2025100308413841000_9.11.e003675.7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00032","article-title":"Starved and asphyxiated: How can CD8+ T cells within a tumor microenvironment prevent tumor progression","volume":"7","author":"Zhang","year":"2016","journal-title":"Front Immunol"},{"key":"2025100308413841000_9.11.e003675.8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101644"},{"key":"2025100308413841000_9.11.e003675.9","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/mt.2013.133","article-title":"DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature","volume":"21","author":"Chi Sabins","year":"2013","journal-title":"Mol Ther"},{"key":"2025100308413841000_9.11.e003675.10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0387"},{"key":"2025100308413841000_9.11.e003675.11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25766"},{"key":"2025100308413841000_9.11.e003675.12","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27589"},{"key":"2025100308413841000_9.11.e003675.13","first-page":"6831","article-title":"Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model","volume":"15","author":"Song","year":"2018","journal-title":"Oncol Lett"},{"key":"2025100308413841000_9.11.e003675.14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1261"},{"key":"2025100308413841000_9.11.e003675.15","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0552-x"},{"key":"2025100308413841000_9.11.e003675.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0305"},{"key":"2025100308413841000_9.11.e003675.17","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0070-4"},{"key":"2025100308413841000_9.11.e003675.18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02985","article-title":"TCR convergence in individuals treated with immune checkpoint inhibition for cancer","volume":"10","author":"Looney","year":"2019","journal-title":"Front Immunol"},{"key":"2025100308413841000_9.11.e003675.19","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/jcmm.13326","article-title":"Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib","volume":"22","author":"Giallongo","year":"2018","journal-title":"J Cell Mol Med"},{"key":"2025100308413841000_9.11.e003675.20","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.leukres.2018.01.010","article-title":"Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study","volume":"66","author":"Najima","year":"2018","journal-title":"Leuk Res"},{"key":"2025100308413841000_9.11.e003675.21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.imbio.2009.03.008","article-title":"Induction of IP-10\/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma","volume":"215","author":"Mohty","year":"2010","journal-title":"Immunobiology"},{"key":"2025100308413841000_9.11.e003675.22","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0329"},{"key":"2025100308413841000_9.11.e003675.23","first-page":"F551","article-title":"Expression of carbonic anhydrase IV mRNA in rabbit kidney: stimulation by metabolic acidosis","volume":"272","author":"Winkler","year":"1997","journal-title":"Am J Physiol"},{"key":"2025100308413841000_9.11.e003675.24","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"2025100308413841000_9.11.e003675.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8"},{"key":"2025100308413841000_9.11.e003675.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1906-8"},{"key":"2025100308413841000_9.11.e003675.27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30663"},{"key":"2025100308413841000_9.11.e003675.28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25766"},{"key":"2025100308413841000_9.11.e003675.29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1399"},{"key":"2025100308413841000_9.11.e003675.30","first-page":"6451","article-title":"Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine","volume":"61","author":"Banchereau","year":"2001","journal-title":"Cancer Res"},{"key":"2025100308413841000_9.11.e003675.31","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31816a8910"},{"key":"2025100308413841000_9.11.e003675.32","first-page":"998","article-title":"Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma","volume":"9","author":"Butterfield","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2025100308413841000_9.11.e003675.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2856"},{"key":"2025100308413841000_9.11.e003675.34","first-page":"6831","article-title":"Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model","volume":"15","author":"Song","year":"2018","journal-title":"Oncol Lett"},{"key":"2025100308413841000_9.11.e003675.35","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01232","article-title":"Immunomodulatory activity of tyrosine kinase inhibitors to elicit cytotoxicity against cancer and viral infection","volume":"10","author":"Climent","year":"2019","journal-title":"Front Pharmacol"},{"key":"2025100308413841000_9.11.e003675.36","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106357","article-title":"Tyrosine kinase inhibitors modulate dendritic cell activity via confining c-Kit signaling and tryptophan metabolism","volume":"82","author":"Chu","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2025100308413841000_9.11.e003675.37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00131","article-title":"Human dendritic cell functional specialization in steady-state and inflammation","volume":"5","author":"Boltjes","year":"2014","journal-title":"Front Immunol"},{"key":"2025100308413841000_9.11.e003675.38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"2025100308413841000_9.11.e003675.39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/14760584.2015.966694","article-title":"Sexual dimorphism in immunity: improving our understanding of vaccine immune responses in men","volume":"14","author":"Furman","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"2025100308413841000_9.11.e003675.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2015.02.004"},{"key":"2025100308413841000_9.11.e003675.41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00281-018-0723-8","article-title":"Sex differences in autoimmune disorders of the central nervous system","volume":"41","author":"Gold","year":"2019","journal-title":"Semin Immunopathol"},{"key":"2025100308413841000_9.11.e003675.42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000496"},{"key":"2025100308413841000_9.11.e003675.43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00552","article-title":"Sexual dimorphism of immune responses: a new perspective in cancer immunotherapy","volume":"9","author":"Capone","year":"2018","journal-title":"Front Immunol"},{"key":"2025100308413841000_9.11.e003675.44","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93433","article-title":"Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy","volume":"2","author":"Loo","year":"2017","journal-title":"JCI Insight"},{"key":"2025100308413841000_9.11.e003675.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.015"},{"key":"2025100308413841000_9.11.e003675.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.04.016"},{"key":"2025100308413841000_9.11.e003675.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"2025100308413841000_9.11.e003675.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"2025100308413841000_9.11.e003675.49","doi-asserted-by":"crossref","first-page":"99336","DOI":"10.18632\/oncotarget.22242","article-title":"The sexist behaviour of immune checkpoint inhibitors in cancer therapy?","volume":"8","author":"Botticelli","year":"2017","journal-title":"Oncotarget"},{"key":"2025100308413841000_9.11.e003675.50","doi-asserted-by":"crossref","DOI":"10.1186\/s41073-016-0007-6","article-title":"Sex and gender equity in research: rationale for the SAGER guidelines and recommended use","volume":"1","author":"Heidari","year":"2016","journal-title":"Res Integr Peer Rev"},{"key":"2025100308413841000_9.11.e003675.51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/21645515.2020.1771986","article-title":"Efficacy of immune checkpoint inhibitors in different types of melanoma","volume":"17","author":"Rossi","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2025100308413841000_9.11.e003675.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.053"},{"key":"2025100308413841000_9.11.e003675.53","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","article-title":"Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity","volume":"21","author":"Lai","year":"2020","journal-title":"Nat Immunol"},{"key":"2025100308413841000_9.11.e003675.54","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/pcmr.12866","article-title":"T-cell receptor diversity as a prognostic biomarker in melanoma patients","volume":"33","author":"Charles","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"key":"2025100308413841000_9.11.e003675.55","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00262-020-02833-z","article-title":"Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients","volume":"70","author":"Naidus","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2025100308413841000_9.11.e003675.56","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0274"},{"key":"2025100308413841000_9.11.e003675.57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33307-z","article-title":"Identification of a Novel OX40L+ Dendritic Cell Subset That Selectively Expands Regulatory T cells","volume":"8","author":"Marinelarena","year":"2018","journal-title":"Sci Rep"},{"key":"2025100308413841000_9.11.e003675.58","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0114-T"},{"key":"2025100308413841000_9.11.e003675.59","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.molimm.2013.08.003","article-title":"BTNL8, a butyrophilin-like molecule that costimulates the primary immune response","volume":"56","author":"Chapoval","year":"2013","journal-title":"Mol Immunol"},{"key":"2025100308413841000_9.11.e003675.60","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56984-w","article-title":"Transcription factor Tlx1 marks a subset of lymphoid tissue organizer-like mesenchymal progenitor cells in the neonatal spleen","volume":"9","author":"Ueno","year":"2019","journal-title":"Sci Rep"},{"key":"2025100308413841000_9.11.e003675.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.01.056"},{"key":"2025100308413841000_9.11.e003675.62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00011"},{"key":"2025100308413841000_9.11.e003675.63","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96113"},{"key":"2025100308413841000_9.11.e003675.64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imr.12789","article-title":"Regulation of immune system development and function by Cbl-mediated ubiquitination","volume":"291","author":"Li","year":"2019","journal-title":"Immunol Rev"},{"key":"2025100308413841000_9.11.e003675.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2005.12.035"},{"key":"2025100308413841000_9.11.e003675.66","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1215"},{"key":"2025100308413841000_9.11.e003675.67","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.16.1.359"},{"key":"2025100308413841000_9.11.e003675.68","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.120"},{"key":"2025100308413841000_9.11.e003675.69","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1129-9"},{"key":"2025100308413841000_9.11.e003675.70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594775","article-title":"Tumor cell-secreted ISG15 promotes tumor cell migration and immune suppression by inducing the macrophage M2-like phenotype","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:41:51Z","timestamp":1759506111000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":70,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,15]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/jitc-2021-003675"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003675","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}